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INTRODUCTION 
Systemic sclerosis (scleroderma) is a generalized disorder of 
connective tissue characterized clinically by thickening & fibrosis of skin & 
by distinctive forms of involvement of internal organs notably heart, lungs, 
kidneys, gastrointestinal tract. The etiology & pathogenesis are unknown(7). 
It is characterized by fibrotic arteriosclerosis of peripheral & sytemic 
vasculature 
• variable degrees of extracellular matrix accumulation (mainly 
collagen) occur in both skin & viscera. 
• associated with specific antibodies most notably anti-
centromere & anti-scl-70 (anti topoisomerase) (1). various 
subsets with specific clinical features & variable involvement of 
various organs. 
 The incidence of PulmHT varies between 6-60% of pts with 
scleroderma. In diffuse form upto 33% have PulmHT both isolated & in 
association with interstitial lung disease. In patients with limited 
scleroderma formerly referred to as CREST (calcinosis cutis, raynauds 
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phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) upto 
60% have pulmonary hypertension (3,4,5). 
Pulmonary hypertension is defined as a mean pulmonary artery 
pressure exceeding 25mmHg at rest or 30 mm Hg in exercise. When it 
occurs as a manifestation of SSc it is particularly severe & one year survival 
is approximately 55%. (2) 
Studies suggest that both right and left ventricular dysfunction is 
common in scleroderma and that diastolic ventricular dysfunction may occur 
independent of systolic dysfunction.(8) Diastolic dysfunction may be 
primary (myocardial fibrosis) or secondary to pulmonary or systemic 
hypertension 
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AIM OF STUDY 
• To assess the prevalence of pulmonary hypertension in 
scleroderma patients with limited & diffuse forms 
• To differentiate between those pulmonary hypertension due to 
interstitial lung disease (secondary PulmHT) from those 
without ILD (isolated PulmHT)  
• To assess the prevalence of ventricular diastolic dysfunction in 
scleroderma patients 
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REVIEW OF LITERATURE 
EPIDEMIOLOGY; 
Its estimated that new cases of scleroderma(SSc) occur at a rare of 
approximately 18-20 per million of general population per year(9). The 
prevalence & severity of SSc varies among different racial & ethnic 
subgroups 
The limited variant is found more commonly in caucasions  while 
African-American females appear to have increased risk for diffuse 
cutaneous type & younger age of onset(10). The average age of onset is 
approximately 50 years(9).  
GENITIC FACTORS 
Genetic factors have been suggested to have a possible pathogenic 
role in scleroderma. There have been suggestions that chromosomal 
breakage rates are greater in patients with scleroderma. More recent data 
have been based on assessment of variable number tandem repeats, a 
technique that can show chromosomal abnormalities. Another area of a 
potential pathogenic relationship is the theory of microchimerism, in which 
the hypothesis is that patients have a reaction to fetal cells from an early 
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pregnancy or from their parents, after which the patients develop a graft 
versus host-like reaction that results in scleroderma. 
Conversely, the work of Reveille et al(60) Suggests that DQ7 and 
DQ5 are more common. It was shown that patients with limited scleroderma 
and anticentromere antibodies were associated with HLA-DR-1, and  
diffuse scleroderma and antitopoisomerase antibody were associated with 
HLA-DR-5. 
DIAGNOSTIC CRITERIA; 
American college of rheumatology proposed preliminary criteria for 
classification based on clinical & lab assessments 
Major: 
Sclerodermatous skin change in any location proximal to 
metacarpophalangeal joints was the single major criterion 
Minor: 
Sclerodactyly, digital pitting scars on fingertips, or loss of digital 
finger pad substance & bibasilar pulmonary fibrosis 
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CLASSIFICATION; 
Patients with scleroderma are classified into subsets of disease by the 
degree of clinically involved skin.  
1.  diffuse; skin thickening present on trunk in addition to face, 
proximal & distal extremities. 
2.  limited: skin thickening limited to sites distal to elbow & knee 
also involving face & neck 
3.  sine scleroderma: characteristic internal organ manifestations, 
vascular, serologic, abnormalities but without clinically 
detectable skin change 
4. In overlap. 
DIFFUSE CUTANEOUS SCLERODERMA: 
In general, patients with diffuse disease have a narrow interval 
between onset of Raynauds phenomenon, skin thickening & internal organ 
involvement.the early stage of SScs characteriased by inflamed edematous 
skin & significant systemic manifestations such as fatigue arthalgias, & 
elevated ESR. 
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There is also a significant risk of internal organ involvement 
particularly in first 3 years(12).  
 The higher the skin nscore the greater the risk of renal disease& 
higher mortality. About 10-20% of patients with diffuse disease will develop 
life threatening internal organ Disease 
The later stages are characterised by gradual softening of skin(11). 
Predictors of higher mortality include higher skin scores (Rodnanscore >20) 
reduced lung diffusing capacity, elevated ESR & evidence of heart or renal 
involvement. 
LIMITED SCLERODERMA; 
The clinical course, survival & clinical features of limited disease are 
quite different from than in diffuse form. The overall 5 year survival is 80-
85% which is significantly better than in diffuse form(13). 
They often have many years of Raynauds prior to the development of 
other signs & symptoms of SSc. The most common first non Raynauds 
symptom is esophageal dysfunction manifested by dysphagia. 
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The major cause of morbidity & mortality in limited form are severe 
Raynauds Phenomenon with occlusive digital vascular disease.& Pulm.HT. 
PulmHT is the leading cause of mortality in limited disease patients. 
This complication occurs in approximately 10-15% of cases with limited 
disease & often occurs in the absence of interstitial lung disease(ILD) 
PATHOPHYSIOLOGY; 
The three key pathologic features are 
- a unique vascular disease 
- abnormal accumulation of extracellular matrix components, 
- autoimmunity 
RAYNAUDS PHENOMENON; 
In SSc over 90% of patients have intense Raynauds phenomenon 
associated with tissue fibrosis, digital ulceration & on occasion ischemic 
demarcation , digital amputation. 
The severity of Raynauds is a manifestation of both vasospasm & 
structural abnormalities of digital arteries. 
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Compared to normals ,SSc patients have a more pronounced decrease 
of both nutritional & thermoregulatory blood flow skin in response to cold 
temperatures. The reactive hyperemia which normally follows periods of 
digital ischemia is absent in SSc.(14) 
There is good evidence that a generalized vasospastic disorder exists 
in SSc ( systemic Raynauds phenomenon) involving kidney , heart, lungs & 
other viscera. The renal crisis of SSc is a clear example of reversible 
vasoconstriction pf the cortical blood flow to kidney.(15)  
 CUTANEOUS MANIFESTATION; 
The skin disease of scleroderma follows a course characterized by 
three phases: 
• inflammatory edematous phase, 
• indurative phase and  
• atrophic phase. 
In the initial edematous stage, the patient experiences puffiness, 
swelling and a sense of decreased flexibility of the skin, especially in the 
forearms, hands and digits, as well as in the feet. The fingers appear puffy 
 17
with a moon-like fullness of the fingertip and there is loss of normal digital 
creases. Loss of the finger pad and tapering of the finger due to fingertip 
ischemia is often seen during this early phase of SSc.. 
The face can appear expressionless because of reduced capacity to 
smile or move the eyelids or cheeks. The opened mouth becomes circular 
with a remarkable reduction in the maximum oral aperture. Vertical lines or 
furrowing of the skin around the lips gives a pursed-lip The nose becomes 
pinched and the facial creases smooth so that the face has a mouse-like 
appearance (mauskopf) Pigmentary changes of the skin also occur during 
the edematous and fibrotic stages of SSc. The vitiligo pattern gives the skin 
a salt & pepper appearance because of perifollicular sparing of pigment 
loss. On average after 1-3 years of disease activity, the inflammatory and 
fibrotic process gradually stops. . In the late stage of SSc, the skin becomes 
atrophic (especially over the fingers, hands and distal limbs) and thinned, 
with tethering secondary to fibrotic tissue binding to underlying structures. 
Areas of thinned skin can ulcerate with minor trauma, especially in areas 
such as the tip of the elbow, the medial or lateral ankle or over sites of a 
flexion contracture. Flexion contractures of the fingers are very common in 
the diffuse form. In patients with limited skin disease, the fibrotic skin 
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changes are usually limited to the fingers(sclerodactyly). More prominent in 
limited disease are small and large mat-like telangiectasias that appear on 
the face, upper chest, palms, fingertips and mucous membranes. 
Subcutaneous calcinosis, composed of calcium hydroxyapatite deposits at 
sites of trauma such as the forearms, elbows or fingers. 
Pathology in Dermis ; 
The pathologic hallmark of systemic sclerosis is an excessive accumula-
tion of extracellular matrix in the dermis, which leads to taut skin. 
Monotonously similar collagen fibers are present in the reticular dermis and 
there is thinning of the papillary dermis. Capillary loss can be seen in vivo 
in the skin by the technique of wide-field nailfold capillaroscopy 
MUSCULOSKELETAL INVOLVEMENT 
Pain on motion of the ankle, wrist, knee or elbow may be 
accompanied by a coarse 'friction rub caused by fibrinous deposits on the 
tendon sheath. These rubs are detected in approximately 30% of patients 
with diffuse scleroderma(16).  
Muscle weakness is a significant problem in scleroderma and often 
has more than one cause(17). In diffuse scleroderma, muscle atrophy and 
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weakness can result from deconditioning secondary to restricted mobility 
and contractures.  
GASTROINTESTINAL INVOLVEMENT 
Gastrointestinal tract involvement is found in almost every patient 
with scleroderma and is characterized by abnormal motility secondary to 
dysfunctions caused by abnormal innervation, smooth muscle atrophy and 
tissue fibrosis(19).  
OROPHARYNX 
. Many patients with scleroderma have a sensation of dry eyes and 
mouth (the sicca complex). In addition, the majority of scleroderma patients 
with sicca complaints usually do not have antibodies against Ro/SSA or 
La/SSB, suggesting that the mechanism of dry membranes in scleroderma is 
a secondary process different from that seen in Sjogren's syndrome(21). 
ESOPHAGUS 
Esophageal dysfunction affects almost every scleroderma patient, with 
dysphagia and dyspepsia being the most common symptom. The dysphagia 
is usually described, as solid foods sticking after normal initiation of 
swallowing. This sensation is relieved by the intake of extra fluids to clear 
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the esophagus. Substernal burning pain may be coupled with a feeling of 
indigestion or nausea. These reflux symptoms are typically worse after 
meals, with exercise and after bedtime. Severe esophageal reflux and 
esophagitis occur equally in patients with either limited or diffuse 
scleroderma.. 
Low or absent primary and secondary peristalsis of the distal esopha-
gus and low lower esophageal sphincter pressure in the presence of a normal 
proximal (striated muscle) esophagus are typical manometric findings in 
scleroderma(22). Excessive air in the esophagus is commonly detected on 
routine chest X-ray. Although symptoms are a poor guide to the degree of 
esophageal disease, patients who are asymptomatic on or off treatment are 
unlikely to have significant complications. Esophagitis appears to occur only 
in patients with impaired peristalsis and delayed acid clearance(23) 
If there is unexplained weight loss with poor caloric intake or other 
symptoms of esophageal dysfunction, a barium swallow orendoscopic and/or 
manometric investigation of the esophagus are warranted. A 24-hour pH 
probe study is a helpful method to quantify the degree and frequency of acid 
reflux in difficult- to-manage cases. 
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STOMACH AND SMALL BOWEL 
Delayed emptying of the stomach with retention of solid foods aggra-
vates reflux and is a frequent cause of bloating. Antral vascular ectasia 
(watermelon stomach) can be a cause of gastrointestinal bleeding in 
scleroderma patients. Endoscopy of these patients reveals antral gastritis and 
prominent longitudinal vascular folds that resembles the surface of a 
watermelon (24). 
. 
LARGE BOWEL 
The large intestine and rectum are also affected by scleroderma. 
Scleroderma patients have decreased distensibility of the colon that does not 
necessarily correlate with symptoms(25). Because of muscular atrophy of the 
bowel wall, asymptomatic wide mouthed diverticula unique to scleroderma 
are commonly found in the transverse and descending colon .  
PULMONARY INVOLVEMENT 
Lung involvement in SSc is almost universal & now accounts for 
significant lifetime morbidity & is leading cause of death. Both interstitial 
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fibrosis & pulmonary vascular are present in the lungs of patients with SSc 
but one pathologic process will be dominant cause of clinical problems. 
Interstitial fibrosis is more likely to be severe in diffuse form while 
pulmonary vascular disease & PulmHT can be dominant in LC form. 
Approximately 80% of patients will have abnormal PFT’s.(26) 
Patients with ILD commonly have a rapid decline in pulmonary 
function in conjunction with progressive lung disease. Dyspnea on exertion 
without chestpain is the most common presenting complaint with a dry 
cough being a late manifestation Of ILD. 
The most common changes in PFT are either a reduced diffusion 
capacity, or a reduced lung volumes( FVC,) typical of restrictive ventilatory 
defect with associated reduction on gas exchange. 
A HRCT scan of chest is a very sensitive indicator for detecting 
changes in lung parenchyma. Finding of ground glass opacities of lung in 
HRCT corresponds to active alveolitis & progressive restrictive lung 
disease. 
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Broncho-alvelolar lavage is used to detect inflammation & active 
alveolitis. BAL demonstrates an increased percentage of neutrophils, 
esinophils or CD 8 cells. When disease progresses, there is worsening 
interstitial fibrosis & honey combing of lung parenchyma (27,28). 
Pulmonary arterial vascular disease with PulmHT is one the most 
difficult clinical problems in SSc. The pulmonary vascular process can be 
indolent & remain clinically undetectable until severe irreversible PulmHT 
& signs of right sided heart failure develops. 
Pulmonary hypertension can be detected early and non-invasively by 
measuring the pulmonary artery pressure with two-dimensional Doppler 
echocardiography. Pulmonary function testing often reveals an isolated 
decrease in diffusion capacity when pulmonary vascular disease is present. 
The natural history of the lung disease in scleroderma is highly vari-
able; the majority of patients will have an early but modest decline in 
function and then follow a stable course or improve. Approximately a third 
will have a more severe progressive decline in lung function that continues 
for 4-5 years and then appears to stabilize. Patients with diffuse skin changes 
tend to have serious lung involvement in the first 5 years of disease, while 
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patients with CREST syndrome usually do not experience clinical symptoms 
until more than 5 years after diagnosis. Risk factors for serious restrictive 
lung disease are African-American or Afro-Caribbean race and 
antitopoisomerase antibodies (29). A low diffusing capacity (less than 40% 
predicted) (30) or rapidly declining DLco and/or lung volumes predict a high 
mortality rate. 
In predicting the histological pattern, CT, although useful, has not 
replaced lung biopsy as the ‘gold standard’ investigation. As yet, patients 
who appear to have early changes on CT should still be considered for a 
thoracoscopic biopsy for staging of the disease. In systemic sclerosis the 
predominant histological pattern is NSIP whereas in IPF the majority show 
UIP. 
Less common problems of the lung include aspiration pneumonia 
(secondary to severe esophageal dysfunction), endobronchial telangiectasias, 
pulmonary hemorrhage, bronchiolitis obliterans organizing pneumonia, 
pleural reactions and pneumothorax. 
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 Studies are inconclusive about the association between pulmonary 
function impairment and abnormal esophageal function(31). There is likely 
an increased risk of lung cancer in patients with ILD(32).  
HISTOLOGY; 
The histology of fibrotic lung disease is that of expansion of the nor-
mally thin alveolar wall interstitial space with the deposition of collagenand 
other connective tissue components. Progressive collagen accumulation with 
diminution of the alveolar air space volume, so that ultimately there is more 
fibrous tissue than air space a gas diffusion blockade, an increase in the 
alveolar—arterial Po2 gradient and ventilation-perfusion inequalities. 
PULMONARY HYPERTENSION IN SSC; 
 Pulmonary arterial hypertension is a life threatening complication of 
both diffuse & limited scleroderma (including CREST syndrome). 
pulmonary vascular disease has a particularly adverse effect on prognosis. 
The incidence of PulmHT varies between 6-60% of pts with 
scleroderma(2,3,4) .In diffuse form upto 33% have PulmHT both isolated & 
in association with interstitial lung disease .In patients with limited 
scleroderma formerly referred to as CREST (calcinosis cutis, raynauds 
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phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) upto 
60% have pulmonary hypertension 
While not all patients. have clinically significant pulmonary 
hypertension, two thirds of patients with scleroderma will have pathologic 
evidence of pulmonary vascular disease(33 ,34)  
Stupi et al reported two year survival un patients with in patients 
without pulmonary hypertension to be greater than 80% while patients with 
pulmonary hypertension had a two year survival of 40%(59). 
Sacks et al reported two year survival of patients with pulmonary 
hypertension & either diffuse or limited forms to be approx. 50%(36). 
Koh et al reports 40% survival in patients with scleroderma & 
pulmonary hypertension compared with higher survival in scleroderma 
patients without organ failure or with other lung involvement (i.e interstitial 
lung disease) at two years.(37) 
 PATHOGENESIS: 
The etiology of pulmonary hypertension in scleroderma spectrum 
disorders remains obscure. There appears to be a direct involvement of 
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pulmonary circulation with direct involvement of pulmonary circulation 
with intimal proliferation & medial hypertrophy similar to that seen in 
primary pulmonary hypertension(38). Some cases may also be related to 
severe pulmonary parenchymal disease, such as interstitial disease with 
hypoxemia. 
Additionally diastolic dysfunction of right &left ventricles has been 
seen in patients with scleroderma & may contribute to pulmonary 
hypertension(39) 
Autoimmune processes have been implicated in the pathogenesis of 
pulmonary hypertension although the mechanism is not known. Positive 
antinuclear antibodies are frequently found in pulmonary hypertension 
patients without a diagnosis of connective tissue disease & pulmonary 
hypertension can occur before the onset of an identifiable connective 
disease. 
AUTO-ANTIBODIES IN SCLERODERMA & PULMONARY HYPERTENSION; 
In patients with scleroderma anti-centromere &anti-histone antibodies 
have been associated with vascular disease. Anti-centromere Ab‘s are 
primarily seen in limited disease. Since patients with limited form have a 
higher incidence of pulmonary hypertension than diffuse disease , it is not 
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surprising that anti-centromere antibodies associated with a higher incidence 
of pulmonaryhypertension Anti-fibrillarin antibodies (anti-u3- RNP) are 
frequently found in diffuse form associated with pulm.HT(40). Anti-
endothelial Ab’s (aECA) are present in 40% & 13% of diffuse form & 
CREST respectively & are associated with pulm.HT & digital infarcts (41). 
In scleroderma & pulm.HT ,when accompanied by HLA-B 35 antigen, anti-
topoisomeraseII Ab’s & antibodies to fibrin bound tissue type plasminogen 
are more common.(42) 
RAYNAUDS & PULM.HT; 
 Raynauds phenomenon , vasospasm of arterioles in distal systemic 
circulation, is commonly reported in scleroderma. In one report all patients 
with Pulm.HT & CREST had raynauds while 68% without Pulm.HT had 
raynauds .Raynauds is also common in patients with SLE & MCTD & 
Pulm.HT. but only 10-14% of patients with primary pulmonary hypertension 
have Raynauds(45). This observation has led to the Pulmonary Raynauds 
hypothesis that vasospasm contributes to the development of Pulm.HT(46) 
Acute hypoxic pulmonary vasoconstriction may be more pronounced 
in patient’s with pulm.HT & scleroderma than in patients with primary 
Pulm.HT(45). however another report found that pulmonary vasospasm was 
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not present in patients with raynauds & scleroderma without Pulm.HT.(46) 
In support of this hypothesis ,patients have defective endothelial dependent 
vasodilatation &this may be related to decreased endothelial nitric oxide 
synthse (eNOS). (47) althogh controversial , decreased lung eNOS has been 
reported in severe primary pulm.HT. while the level of eNOS in connective 
tissue is not known. decreased production of lung nitric oxie has been found 
in patients with scleroderma & Pulm.HT. similarly expression of 
prostacyclin synthasr in pulmonary endothelium may be decreased in 
patients with severe connective tissue disease associated Pulm.HT 
Endothelin -1 is increased in serum of patiensts with both diffuse & limited 
forms(48) & while endothelin levels correlate with survival in patients with 
scleroderma they are not higher in those with Pulm.HT.(49) In contrast 
higher serum endothelin levels are found in patients with SLE associated 
Pulmonary hypertension than in non- Pulmonary hypertension patients.The 
role of endothelin-1 in Pulmonary hypertension has led to the uase of 
endothelin antagonists(Bosantan ) in connective tissue disease associated in 
Pulmonary hypertension(50)..Serotonin may also play a role in pathogenesis 
of Pulmonary hypertension.In scleroderma platelet serotonin levels are 
decreased & serum levels are increased  
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DIASTOLIC DYSFUNCTION IN SCLERODERMA 
Diastolic dysfunction is defined as the deterioration of the ventricular 
filling capacity without any compensatory increase in the left atrial pressure. 
(74) Another definition is the abnormal ventricular filling defect causing 
cardiac output inadequacy. (75) In patients with diastolic dysfunction, the 
deterioration of ventricular dilatation (early diastole), decrease in 
compliance (early late diastole) or an external pressure in pericardium can 
lead to problems in ventricular filling. Cardiomyopathies, constructive 
pericarditis, ischemic heart diseases, volume overload (mitral insufficiency, 
arteriovenous fistulae), mitral and tricuspid valve stenosis may cause 
diastolic dysfunction.  
Guinta et al(39) have pointed out an impaired left ventricular filling in 
a significant percentage of SSc patients in whom no other cause of diastolic 
dysfunction had been detected is likely to depend on either myocardial 
fibrosis or ischemia or both.(52,53) As myocardial fibrosis as well as small 
intra myocardial coronary vessel are known to affect both right &left 
ventricle in SSc an altered LV & RV filling is likely to occur in this 
disease(54,55) 
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An abnormal right ventricular filling is detected in 40% of SSc 
patients. Such alteration was detected in many without clinically evident 
cardiac disease & resulted to be correlated with both left ventricular diastolic 
abnormalities & Pulmonary hypertension. 
  
Scleroderma heart disease is subclassified into primary & secondary 
formsPrimary cardiac disease in SSc depends on involvement of 
myocardium & or pericardium &small intramyocardial vessels by SSc itself. 
Secondary cardiac involvement develops either in patients with systemic 
hypertension induced by renal scleroderma (LV disease) & in those with 
pulmonary vascular & or interstitial lung disease. 
SSc myocardial fibrosis is different from that occurring in patients 
with coronary atherosclerosis. Actually SSC myocardial fibrosis is equally 
distributed throughout the right & left ventricle, does not involve the 
immediate subendocardial layers, is not related to the distribution of 
epicardial coronary vessel & is not associated with hemosiderin deposits. 
 Left ventricular filling abnormalities in SSc were detected in studies 
by Maoine et al(52) & Valentine et al.(53) Regarding right ventricular 
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dysfunction Candell-Riera et al detected a significantly low Tr E/A ratio in 
63 % of patients. (56) 
 PATHOGENESIS: 
The pathogenesis of the cardiac lesion in scleroderma is controversial. 
An intriguing concept is one of repetitive vascular insults secondary to cold 
induced perfusion changes. Classic pathological changes of contraction band 
necrosis seen in scleroderma are similar to the findings in hearts subjected to 
prolonged ischemia and subsequent reperfusion.  
MYOCARDIAL INVOLVEMENT: 
Myoccardial lesions and fibrosis which are found in up to 80 percent 
of patients upon autopsy, may be patchy, may present in both ventricles and 
may be patchy may present in both ventricles and may bear no relationship 
to myocardial perfusion.. 
 Myocardial dysfunction occurs often although clinical congestive 
heart failure occurs in less than 5 per cent of patients with progressive 
systemic sclerosis. 
 Using extensive noninvasive techniques, left ventricular dysfunction 
and myocardial perfusion defects can be detected in up to 75% of patients. 
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Ischemic chest pain and myocardial infarction are uncommon clinical 
problems in scleroderma. Thallium perfusion defects reflecting vascular 
disease of the endomyocardial vessels (not larger coronary arteries) are seen 
among scleroderma patients both at rest and with exercise. Because of this, 
the scleroderma patient with angina-like chest pain may need angiographic 
studies to rule out coronary arteriosclerosis because thallium scans are likely 
be abnormal as a result of the microvascular disease of scleroderma heart. 
 In fact, cold provocation of Raynaud's phenomenon can temporarily 
increase the number of thallium scan defects and induce local abnormalities 
in ventricular wall motion, supporting the notion that reversible vasospasm 
of the myocardial microcirculation occurs in scleroderma. Thallium scan 
perfusion defects predict more severe myocardial disease and poor outcome. 
Patchy myocardial fibrosis is a fairly common finding at autopsy in 
scleroderma patients(56) This finding is thought to occur secondary to 
ischemia-reperfusion events in the heart microvasculature causing con-
traction band necrosis of heart muscle. A decline in left ventricular ejection 
fraction is a late clinical manifestation, primarily in patients with diffuse 
skin disease. An abnormal left ventricular ejection fraction is demonstrated 
by radionucleotide scanning during exercise in approximately 40-50% of all 
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patients, and approximately 15% of diffuse scleroderma patients have 
abnormalities at rest. Echocardiographic studies suggest that both right and 
left ventricular dysfunction is common in scleroderma and that diastolic left 
ventricular dysfunction may occur independent of systolic dysfunction. 
Diastolic dysfunction may be secondary to hypertension (with or without 
renal disease) or myocardial fibrosis and may manifest with abnormal left 
ventricular compliance and pulmonary vascular congestion. Unexplained 
dyspnea on exertion may be the initial clinical manifestation of 
unappreciated diastolic dysfunction. 
PERICARDIAL INVOLVEMENT 
Autopsy series report pericardial involvement in up to 50 per cent of 
patients with systemic sclerosis. Pericardial involvement includes fibrinous 
pericarditis, pericardial adhesions and pericardial effusions 
ECG changes in SSC 
Electrocardiography or Holter monitoring often shows conducting 
system disease or arrhythmias, which are usually clinically silent. Premature 
ventricular contractions are the most common arrhythmia; frequently they 
are in couplets or are multifocal. Premature atrial contractions, 
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supraventricular tachycardia, AV or intraventricular conduction disorders 
are seen less commonly(57).  
RENAL INVOLVEMENT; 
The most important clinical manifestation of scleroderma kidney is 
accelerated hypertension and/or rapidly progressive renal failure: the 
scleroderma renal crisis(58) Surveys suggest that only about 10-15% of all 
scleroderma patients develop a crisis. The majority of patients who develop 
renal crisis have diffuse cutaneous disease and approximately 80% of cases 
of renal crisis occur within 4 years of disease onset. Risk factors for renal 
crisis include rapidly progressing diffuse skin disease, tendon friction rubs, 
new unexplained anemia and the presence of anti-RNA polymerase III 
antibody. Antecedent use of corticosteroids is also associated with a higher 
risk of developing renal crisis. Non-malignant hypertension, abnormalities 
on urinalysis, plasma renin level and the presence of anticentromere or 
antitopoiso-merase antibodies are not predictors of a scleroderma renal 
crisis. 
Patients with renal crisis may present with typical signs of malignant 
hypertension, including headache, altered vision, signs of heart failure and 
confusion or neurologic signs such as seizures in the setting of an 
abnormally high blood pressure (>150/90mmHg) . 
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The typical vasculopathy of scleroderma is present in the renal vessels of 
patients with or without renal crisis. This suggests that other factors, such as 
vasospasm, probably contribute to the development of renal crisis. 
Scleroderma patients may have a reduced creatinine clearance, proteinuria, 
microscopic hematuria and non-malignant hypertension, but often another 
cause for these abnormalities is found. For example, an immune complex 
process may be the cause for glomerulonephritis in patients with an overlap 
syndrome of SLE and scleroderma. A reversible proteinuria or even a 
crescentic glomerulonephritis may occur secondary to treatment with D-
penicillamine 
CLINICAL PRESENTATION & EVALUATION: 
. Popular clinical measurements include skin score, hand extension, oral 
aperture/ finger flexion and global patient and physician assessments of disease 
activity. Most clinical observations detail the cutaneous manifestations because 
the skin is directly measurable by observation and palpation. Although the 
natural course of the skin changes is reasonably well described in diffuse 
scleroderma, it must be remembered that the cutaneous disease may not be the 
ideal surrogate for the overall disease activity. For example, significant 
cardiopulmonary and gastrointestinal disease can emerge later in the course, 
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at a time when the skin may be improving or thinning. In limited 
scleroderma, the skin fibrosis is minimal and does not parallel the vascular 
disease such as pulmonary hypertension and digital loss. 
Recently, a quantitative measure of disease severity has been developed 
that documents Degree of severity of involvement of each major organ graded 
from 0 (normal) to 4 (end-stage) . This scale has been externally validated on a 
large group of scleroderma patients and may be helpful in comparing groups of 
patients in clinical trials and for following disease in individual patients. 
Dyspnea is the most common presenting symptom of SSc associated 
pulmonary hypertension. the clinical evaluation is similar to that of primary 
pulmonary hypertension. History & physical examination often reveal 
findings of underlying connective tissue disease. 
Since around 15% SSc patients may develop PAH & in most cases 
asymptomatic its important to monitor them regularly for this complication . 
The British cardiac society guidelines recommend that patients with LCC 
particularly those whom are anticentromere antibodies positive should be 
screened by transthroacic echo annually even if they have no symptoms(2).  
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Screening for PAH is certainly worthwhile in these high risk patients 
since it’s the only way to identify PAH earlier & begin treatment earlier. 
Although PAH is incurable, it can now be contained for many years through 
use of new effective treatments for this condition .We now have a greater 
incentive to identify PAH patients & manage them through combined clinics 
with rheumatologist working together with cardiologist, pulmonologist & 
pulmHT nurses(2). Doppler echo has emerged .as a reliable & reproducible 
means of non invasively assessing pulmonary artery systolic pressure(PASP) 
& has been employed to detect Pulm.Ht in patients with connective tissue 
disease. 
.Denton et al ( 61) performed Doppler echocardiography to estimate 
the trucuspid gradient(TG), an indirect & observer dependent measure of 
pul;monary artery elevation on 33 consecutive SSc patients clinically 
suspected to have PAH.they subsequently confirmed the diagnosis in 21 of 
these patients (64%). Echo correctly identified 19 of these patients , giving a 
sensitivity of 90% & specificity of 75%. Interestingly they noted a 
difference of upto 29 mm Hg between echo & catheter Findings. The authors 
concluded echo is a useful non-invasive, initial screening tool. The role of 
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carbon monoxide diffusing capacity as a non- invasive measure of PAH is 
less certain. 
 Stupi et al (59) & Ungerer et al (6) have demonstrated an association 
between DLCO <40-55% & isolated SSc PAH in a total of 89 patients. 
 Burke et al (60)& Jezek & widimsky etal(62) were unable to confirm 
a clear link between low DLCO & PAH. 
Mukerjee (76)et al suggested echo estimated TG or PASP & DLCO, 
most commonly used screening tools for SScPAH, perform well only in the 
diagnosis of advanced pulm.HT. 
Echo perfomed better in identifying patients who require urgent 
referral & treatment for advanced disease. Patients suspected of advanced 
disease in SSc & Pah have an annual mortality of 40%. Relying on echo 
alone to identify these patients results in a high false negative rate of 42% 
.however combining 3D echo & clinical findings ( modified NYHA dyspnea 
grade ) identifies > 90% of patients with advanced PAH.  
Echo has been used to evaluate ventricular diastolic function M –
mode techniques have been used to record the rate of relaxation of 
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ventricular cavity. This technique utilizes digitalization of the borders of left 
ventricular cavity, with which the left ventricular dimension increases in 
early diastole being noted 
Doppler echo currently is the primary technique used for evaluating 
ventricular diastolic function.. With normal pressures the early diastolic 
mitral velocity (E) exceeds that following atrial systole or late mitral(A) 
velocity  (E/A greater than 1) 
Under several conditions one of which is normal aging , the velocity 
in early diastole decreases & the late velocity increases. Among the 
pathologic states that. produce this change are LV hypertrophy. & 
myocardial ischemia.both conditions produce abnormal relaxation & 
decreased early velocity into LV. This situation will commonly produce 
elevated LV diastolic pressures unusually low filling pressures in lefty 
atrium may also have a similar pattern. 
If the LV filling pressure is markedly elevated, as may occur in severe 
heart failure, then the LV inflow velocity pattern changes dramatically. Now 
there is a marked increase in early diastolic velocity with an increase in E 
velocity.  
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The atrial velocity is now reduced. This type of mitral flow may also 
occur if there is a restrictive pattern of filling of LV as may occur with 
restrictive cardiomyopathy.  
ABNORMAL PATTERNS 
Impaired Myocardial Relation Pattern 
In nearly all types of cardiac disease, the initial abnormality of 
diastolic filling is slowed or impaired myocardial relaxation , include LV 
hypertrophy, hypertrophic cardiomyopathy, and myocardial 
ischemia/infarction. The Isovolumic relaxation time(IVRT) is prolonged. 
Mitral E velocity is decreased and A velocity is increased, roducing and E/A 
ratio<1, with prolonged DT. 
Whenever the E/A ratio is below 1, impaired relaxation is usually 
present.  
RESTRICTIVE FILLNG (or Decreased Compliance) PATTERN: 
The term restrictive diastolic filling, or restrictive physiology, should 
be distinguished from restrictive cardiomyopathy. Restrictive physiology 
can be present in any cardiac abnormality or in a combination of 
abnormalities that produce decreased LV compliance and markedly 
increased LA pressure. Examples include patients with decompensated 
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congestive heart failure, advanced restrictive cardiomyopathy, severe 
coronary artery disease, acute severe aortic regurgitation, and consrtrictive 
pericarditis. 
The increase in LA pressure result in earlier opening of the mitral 
valve, shortened IVRT, and a greater initial transmitral gradient(high E 
velocity). Early diastolic filling into a noncompliant LV cause a rapid 
(increase in early LV diastolic pressure, with rapid equalization of LV and 
LA pressures producing a shortened DT, Atrial contraction increased LA 
pressure increases even more rapidly, when LV diastolic pressure is 
markedly increased, there sure is markedly increased, there may be diastolic 
mitral regurgitation during mid-diastole or with atrial relaxation. Therefore, 
restrictive physiology is characterized by mitral flow velocities that show 
increased E velocity, decreased A velocity (<<E), and shortened DT(<160 
msec) and IVRT (<7 msec). Typically, the E/A ratio is greater than 2... 
PSEUDONORMALIZED PATTERN: 
As diastolic function deteriorates, a transition from impaired 
relaxation to restrictive filling occurs. During this transition, mitral inflow 
pattern goes through a phase resembling a normal diastolic filling pattern, 
that is, E/A ratio of 1 to 1.5 and normal DT (160 to 200 ms). This is referred 
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to as the pseudonormalized filling pattern and it represents a moderate stage 
of diastolic dysfunction. The pseudonormal pattern can be distinguished 
from a true normal pattern by Doppler  Tissue Imaging(DTI) 
GRADING OF DIASTOLIC DYSFUNCTION: 
. Therefore, diastolic dysfunction can be graded as follows according 
to the diastolic filling pattern. 
Grade 1 = impaired relaxation 
Grade 2 = pseudonormalized pattern 
Grade 3 = reversible restrictive pattern 
Grade 4 = irreversible restrictive pattern. 
 As previously discussed, patients with scleroderma should be 
considered an “at risk” group for the development of pul-monary 
hypertension, and echocardiography may reveal right ventricular 
hypertrophy and dilatation even before the onset of symptoms 
. Ultimately, as with primary pulmonary hypertension, right-heart 
catheterization is needed to confirm the diagnosis, assess hemodynamic 
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severity, and exclude other possible contributing factors, such as an occult 
congenital heart defect. While it is generally thought that patients with 
scleroderma- associated pulmonary hypertension are less likely to 
demonstrate a favorable response to vasodilator therapy than patients with 
primary pulmonary hypertension (in whom the response rate is 
approximately 20% )to its still advocated by some experts.  
 45
MATERIALS AND METHODS 
STUDY POPULATION 
All patients were prospectively identified from rheumatology 
department of our college. There were 40 patients of SSc defined according 
to previously mentioned ACR criteria were studied. Of them 36 were 
females and 4 were males. Of them thirty patients satisfied the criteria for 
limited disease & ten had diffuse disease. 
 Mean age of forty patients is 38.5 years. The average duration of 
illness is 3.5 years. All patients except three had raynauds phenomenon. 
Twenty patients were affected with digital pitting scars & ulcers , & two had 
digital amputation. 
 For comparison twenty normal persons were selected( seventeen 
females, three male) of the same age group. All patients & controls gave 
consent for the study. 
None of the subjects included in the study had evidence of cardiac 
disease, hypertension, diabetes mellitus, chronic obstructive pulmonary 
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disease, pulmonary tuberculosis or pulmonary thromboembolism as assessed 
by history, physical examination 
CLINICAL EVALUATION: 
A questionnaire prepared noted the duration of SSc, extra-cutaneous 
complications, the use of current and previous disease-modifying drugs, . 
Questions were asked relating to previous chest disease, cough, dyspnea, 
sputum production, chest pain, weight loss and risk factors for respiratory 
disease, including smoking, medications, and occupation( exposure to 
silica,solvent industry) .A detailed clinical examination was performed. All 
patients had venous blood taken for full blood count, renal and liver 
function, C-reactive protein and antinuclear antibodies. Patients also 
underwent skin biopsy. 
All patients had a physical examination for signs of pulmonary 
hypertension (Jugular venous distension, Right ventricualar heave, 
Accentuated pulmonary closure sound) & Signs of interstitial lung 
disease(Velcro rales) 
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ELECTROCARDIOGRAM: . 
Patients also had 12 lead ECG that was reviewed for presence of left 
or right atrial enlargement and left or right ventricular hypertrophy. 
ECHOCARDIOGRAM; 
All echocardiograms were performed by two Cardiologists. Whenever 
possible, these cardiologists, who were blinded to clinical details, 
determined pulmonary artery pressure All studies were performed using a 
phased array ultrasonoscope (ALOKA) with a combined 2.5 MHz. 
Imaging/continuous wave Doppler and colour Doppler transducer. 
 Doppler recordings were made from the parasternal, apical and 
subcostal positions using a modified views when appropriate. A systematic 
search was performed using two dimensional and colour flow Doppler to 
identify the most complete tricuspid regurgitant jet followed by continuous 
wave Doppler acquisition of spectral envelopes of greatest maximal velocity 
and density. The systolic transtriuspid gradient was calculated using the 
modified Bernoullie equation 
 P=4V2 
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Where V represents maximal regurgitant velocity in metres per 
second 
TWO DIMENSIONAL ECHOCARDIOGRAPHY 
PulmHT is easily recognized when the following M-mode and 2D 
echocardiographic features are present( ) 
Diminished or absent “a”(atrial) wave of the pulmonary valve 
Midsystolic closure or notching of the pulmonary valve 
Enlarged chambers on the right side of the heart 
D-shaped left ventricular (LV)caviry caused by a flattened ventricular 
septum 
Estimated Right Atrial Pressure(RAP): 
Measurement of inferior vena cava (IVC) diameter was made from 
long axis subxiphoid views. RAP was estimated using caval respiratory 
index as. when the caval respiratory index exceeded 50% the assumed RAP 
was 5mm Hg. When the caval respiratory index was less than 50% the 
assumed RAP was 15 mm Hg.  
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Estimated Pulmonary Artery Systolic Pressure(PASP): 
PASP was calculated as the sum of transtricuspid gradient and the 
estimated RAP. This method is highly accurate over a wide range of 
Pulmonary Artery Pressure. 
 Pulmonary hypertension is defined as a PASP of 25 mm Hg.or 
greater.. In the absence of pumonic stenosis or RV outflow obstruction, RV 
systolic pressure is equal to pulmonary artery systolic pressure. The normal 
TR velocity is 2.0 to 2.5 m/sec. A higher velocity indicates pulmonary 
hypertension, RV outflow tract obstruction, or pulmonic stenosis. 
Mitral Flow Velocities; 
The initial classification of diastolic filling is usually attempted from 
peak mitral flow velocity of the early rapid filling wave(E), peak velocity of 
the late filling wave due to atrial contraction(A), and the E/A ratio. To 
measure E and A velocities reliably, the Doppler velocity recording shoud 
be satisfactory. As mentioned previously, When taken alone, normally E/A 
is bigger than 1; in late relaxation it decreases to below 1 and this is an 
indicator of diastolic dysfunction. (53) We have taken E/A ratio of less than 
1 as suggestive of diastolic dysfunction. 
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DECELERATION TIME; 
The diastolic filling pattern is characterized further by measuring 
deceleration time(DT), the interval from the peak of the E velocity to its 
extrapolation to baseline. DT is prolonged in patients with a relaxation 
abnormality as the predominant diastolic dysfunction, because it takes 
longer for LA and LV pressures to be equilibrated with a slower and 
continued decrease in LV pressure until mid to late diastole. 
Tricuspid Flow Velocities 
Just as mitral flow velocity variables characterize the LV diastolic 
filling pattern, so tricuspid flow velocity recordings characterize the RV 
diastolic filling pattern, using the same criteria. Left and right diastolic 
filling patterns are not necessarily the same in a patient. The main difference 
between mitral and tricuspid velocities is a respiratory variation in tricuspid 
flow velocities in normal subjects. 
In order to differentiate pseudo- normalization pattern ( grade 2 
diastolic dysfunction) from a normal one Doppler tissue imaging was 
performed.  
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 Mitral&Tricuspid Annulus Velocities by Doppler Tissue Imaging(DTI): 
Doppler tissue imaging (DTI), or tissue Doppler, has been applied to 
evaluate diastolic function by measuring mitral & tricuspid annulus velocity 
during diastole. The mitral & tricuspid annulus velocity profile during 
diastole reflects the rate of changes in the long axis dimension and in LV & 
RV volume respectively. When myocardial relaxation is abnormal, the ratio 
of mitral & tricuspid annulus motion during atrial systole to the total 
diastolic annular motion is increased. Sohn et al(77) demonstrated that mitral 
annulus velocity determined by DTI is relatively preload-independent and is 
useful in differentiating pseudonormal(grade 2 diastolic dysfunction) from 
normal mitral inflow velocity pattern. 
Left Ventricular Ejection Fraction(LVEF): 
LVEF was used as an index of LV systolic pump function and was 
calculated by Simonsons formula 
Right Ventricular Accelerated Fractional Shortening( RVAFS): 
The percentage of shortening of RV area during systole was used as 
an index of RV systolic function and was calculated.Fractional shortening 
was calculated as the difference between diastolic and systolic diameters 
divided by diastolic dimension. 
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The following variables were also assessed:  
 The left atrial (LA) and right atrial (RA) areas were traced manually 
and measured at end-systole from the two-dimensional apical four-chamber 
view.& ,right ventricular dimension 
Pulmonary artery pressure control group: 
For the normal population, limited data are available on pulmonary 
artery pressure estimated by Doppler echocardiography. A study of 20 
normal healthy adults by Vachiery et al. (65) using Doppler 
echocardiography found that the maximum estimated pulmonary artery 
pressure was 24 mmHg  
 To assess the diagnostic validity of the results of the echocardiogram, 
a control group of 20 normal persons were subjected for echocardiogram & 
readings were incorporated into the study. Echocardiography was 
undertaken with the same ALOKA echocardiogram machine by the same 
cardiologists who performed the echocardiography in the patients with SSc. 
 Those patients who had PAH (echowise) are advised to undergo PFT. 
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DEFINITIONS 
Pulmonary hypertension:  
The gold standard for pulmonary artery pressure measurement is 
invasive right-heart catheterization. Pulmonary hypertension, defined by 
right-heart catheterization of the pulmonary artery is a pressure of 25 mmHg 
or greater at rest and at least 30 mmHg during exercise (2).  
Echocardiography has now been used widely in patients with cardiac 
disease. Reported correlations between Doppler and catheter measurements 
range from 0.89 to 0.97; the average standard error for systolic pulmonary 
artery pressure ranges from 5 to 9 mmHg, and interobserver variability is 
<3% (83). We have taken Denton et al.'s definition of pulmonary 
hypertension on Doppler echocardiography as an estimated PASP of 25 
mmHg or greater .  
Pulmonary Function Tests; 
Of the 40 patients, 18 patients (9 with limited-type SSc, and 9 with 
diffuse-type SSc) underwent lung function testing within period of 1 week 
after the echocardiography examination. Of these 18 patients, none were 
being treated for pulmonary disease. . Pulmonary function testing was 
performed (Jaeger Masterlab, Body Box 10151, Transfer 10154; Jaeger; 
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Wuerzburg, Germany) according to the recommendations of the American 
Thoracic Society. Values are presented as a percentage of the predicted 
value. 
Significant lung disease: 
Significant lung disease that could be causing pulmonary hypertension 
was defined as pulmonary function measurements outside the normal range: 
a forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) ratio of 
less than 65% or a vital capacity lung volume of less than 80% of the 
predicted value (80,81)  
High-resolution CT (HRCT) of lungs: 
When PFT is abnormal patients were advised to undergo HRCT of 
lungs to see whether they have radiographic evidence of ILD. High 
resolution CT was performed in eighteen of the patients (Philips Tomoscan 
LX; Philips; Eindhoven, the Netherlands). 
 Scans were performed at full inspiration in the supine position with 
120 kV and 175 mA, including continuous scans through the lungs with 10-
min thickness followed by scans with 1.5-mm thickness with a slice spacing 
of 30 mm.  
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When they had ILD they are called secondary pulmonary 
hypertension. When there is no ILD in the presence of significant PulmHT 
they are likely to have isolated PulmHT.  
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STATISTICAL ANALYSIS 
Continuous data were described as mean and standard deviation 
(mean +/- SD), and categorical variables as numbers. Comparisons between 
2 categories were made using Student t test (2 tailed) for continuous 
variables. To analyze categorical data we performed the chi square test. 
Pearson correlation was used to correlate the continuous variables like 
disease duration and pulmonary artery pressure and parameters of diastolic 
dysfunction. 
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RESULTS & OBSERVATION 
There were forty cases with mean age of 35.58+10 years. 
TABLE 1:  DURATION OF DISEASE 
DURATION NO. OF FEMALES NO. OF MALES 
1 YR 3 1 
2YRS 15 1 
3YRS 8 1 
4YRS 3 - 
5YRS 4 1 
>5YRS 3 - 
Adequate images & Doppler spectral envelopes of tricuspid 
regurgitatin were obtained in 37 of 40 patients. The calculated pulmonary 
artery pressure ranged from 16-72 mm of Hg with a mean of 24.41(SD 
15.30) 
Similarly TR JET was identified in 16 controls with a mean PASP of 
18.2(3.55) mm of Hg. Nine patients had PulmHT with calculated PASP 
ranging from 34- 72 mm of Hg. Of them 4 had values above 50 mm Hg No 
patient had impaired left ventricular function, as assessed by left ventricular 
ejection fraction, which could explain pulmonary hypertension. Of those 9 
patients with Pulm.HT 5 had limited disease ; 4 had diffuse form. there were 
8 females & 1 male. 
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 Chest HRCT showed that 4(10%) (1 of limited: 3 of diffuse) patients 
had interstitial lung disease with a fibrosing alveolitis pattern. All the 4 
patients, had lung disease was sufficiently severe to cause significant volume 
loss (as defined above, under significant lung disease) on pulmonary 
function testing.& hence had secondary pulmonary hypertension . So the 
remaining (5) 12.5 % of patients had isolated pulmonary hypertension 
without lung disease evident on pulmonary function testing. [Table 2] 
The One remaining female patient in diffuse category had no evidence 
of ILD ( had a moderately high pulmonaryartery pressure). For this patient a 
second echo was done three months later on the advice of rheumatologist & 
was found to have a tricuspid gradient which had become lower ( reversible) 
TABLE 2: SUBGROUPING THE PATIENTS WITH PulmHT  
LIMITED (N=5) DIFFUSE(N=4) 
 NO. OF 
MALES 
NO.OF 
FEMALES 
NO.OF 
MALES 
NO.OF 
FEMALES 
WITH ILD 0 4 1 2 
WITHOUT ILD 0 1 0 1 
6 other patients who were symptomatic underwent respiratory 
function tests which showed restriction & HRCT evidence of ILD but 
without increased PASP. 
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The clinical features of the SSc patients with pulmonary hypertension 
were compared with those of SSc patients who had a pulmonary artery 
pressure below 25 mmHg. (The findings are shown in the tables3,4,5,6).| 
There was No statistically Significant difference found between the two SSc 
groups in type of SSc, age,sex and disease duration(table ). . Also the acute 
phase response as assessed by C-reactive protein did not differ significantly 
between the two groups.  
In the control group, none of them had pulmonary artery pressure 
above 25 mm of Hg. . The pulmonary artery systolic pressure was higher in 
patients with SSc (24.18+ 15.51 mm Hg) than in controls (18.2+3.55 mm) (P 
=0.003).There was also a weak correlation between the pulmonary artery 
pressure and the age of the patient (r=0.02,). [Figure 1] 
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A comparison of clinical variables in patients with normal & elevated 
PASP is shown in tables 3,4&5 
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Table 3: 
Pul. Hypertension 
No Yes Total 
Limited Type Count % Count % Count % 
No 6 19.4 4 44.4 10 25.0 
Yes 25 80.6 5 55.6 30 75.0 
Total 31 100.0 9 100.0 40 100.0 
Not significant 
Table 4: 
Pul. Hypertension 
No Yes Total 
Diffused Type Count % Count % Count % 
No 25 80.6 5 55.6 30 75.0 
Yes 6 19.4 4 44.4 10 25.0 
Total 31 100.0 9 100.0 40 100.0 
Not significant 
Table 5: 
Pul. Hypertension 
No Yes Total 
Sex Count % Count % Count % 
Female 28 90.3 8 88.9 36 90.0 
Male 3 9.7 1 11.1 4 10.0 
Total 31 100.0 9 100.0 40 100.0 
Not significant 
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Table 6: 
Pul. Hypertension 
No (n = 31) Yes (n = 9) 
 Mean S D Mean S D t Df Sig. (2-tailed) 
Age 34.74 11.12 38.44 7.13 -0.94 38 0.353 
Not significant 
There is no statistically significant differences at baseline in patients 
with or without elevated PASP.  
Echocardiographic and Doppler Differences Between Patients 
With SSc and Controls: 
There was a significant difference between the two groups regarding 
the right ventricular cardiac chamber dimensions (17.7+2.9), compared to 
controls(14.5+3.1)(p< 0.05). But there was no difference between the 
ejection fraction of left ventricle and fractional shortening of the right 
ventricle.[table 7] 
 In SSc patients, we found abnormalities of left ventricular filling 
characterized by increased late diastolic mitral filling velocity A cm/s 
(52.05+10.1vs45+4.20, p=0.006), prolonged deceleration time 
(172.9+14.01vs158.1+5.82, p=0.001) .  
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Moreover in the group of patients we found a weak correlation 
between the deceleration time and disease duration (r= -0.1, ), late diastolic 
tricuspid filling velocity A cm/s and disease duration (r= -0.2, ) 
correlation_0 .2 
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7 patients (17.5%) in the group had E/A ratio of less than 1and this 
was taken as an indicator of diastolic dysfunction. Among the control 
population, none of patients had evidence of diastolic dysfunction. Moreover 
the mean age of patients was 35.8 + 10.1 years and this age cannot explain 
the diastolic dysfunction. The patients with evidence of diastolic dysfunction 
were then compared with SSc patients with E/A ratio more than 1 and the 
results are summarized in table 4. 
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Table 7: 
TYPE 
Control (n = 20) Case (n = 40) 
 Mean S D Mean S D T df Sig. (2-tailed) 
Rt. Ventricular Dimension 14.50 3.00 17.70 2.90 3.98 58 0.000 
Rt. Vetricular thickness 3.95 0.83 4.65 1.61 1.82 58 0.073 
Age 30.35 7.92 35.58 10.39 1.98 58 0.053 
Lt. Ejection Fraction 64.60 3.03 66.15 5.41 1.19 58 0.240 
Diastolic Dysfunction 0.00 0.00 0.18 0.38 2.03 58 0.047 
Pul. Artery Sys. Pressure 18.20 3.55 24.18 15.51 1.69 58 0.096 
DTI Mitral 1.20 0.17 1.24 0.18 0.81 58 0.418 
DTI Tricuspid 1.22 0.17 1.28 0.20 1.30 58 0.200 
Mitral early velocity . . 71.75 6.76    
Mitral late velocity 45.15 4.20 52.05 10.41 2.84 58 0.006 
Mitral DT 158.10 5.82 172.90 14.01 4.52 58 0.000 
Tricuspid early velocity . . 43.53 4.98    
Tricuspid late velocity 38.65 4.74 36.95 5.60 1.16 58 0.249 
Tricuspid early by late 1.20 0.16 1.16 0.27 0.50 58 0.620 
Tricuspid DT 177.15 5.75 175.85 14.62 0.38 58 0.704 
RV fraction shortening 41.80 2.02 43.18 3.63 1.57 58 0.121 
7 patients had diastolic dysfunction.one male & six females. The male 
patient had severe Pulm.HT & diastolic dysfunction of both RV & LV. 
Of the 6 female patients 4 had right ventricular diastolic function (3 
had associated Pulm.HT), 2 had left ventricular diastolic dysfunction (no 
associated systemic hypertension).[table8] 
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Table 8: Subgrouping Of Patients With Diastolic Dysfunction 
RV diastolic 
dysfunction 
LV diastolic 
dysfuntion 
Both RV & LV diastolic 
dysfuntion 
 
With 
PHT 
With out 
PHT 
With 
SHT 
Without 
SHT With PHT Without PHT 
No. of females 3 1 0 2 0 0 
No. of males 1 0 0 0 1 0 
Differences between Patients with SSc with and without Ventricular 
Diastolic Dysfunction 
To further investigate the implication of the ventricular diastolic 
dysfunction in patients with SSc without clinically evident cardiovascular 
disease, we assessed whether patients with SSc who had left ventricular 
diastolic dysfunction had some clinical or investigational peculiarities that 
might help identify these patients.  
However, no statistically significant differences in sex, age were 
found (data not shown). But there was a significant difference in the 
estimated pulmonary artery systolic pressure between patients with and 
without ventricular diastolic dysfunction (40.+19.32vs 
20.82+12.53,P=0.00).[table9] 
Two patient had pericardial effusion.  One 22 year old female patient 
had dilated left atrium & left ventricle with global hypokinesia without 
previous history of myocarditis or infarction. One patient had ECG evidence 
of left bundle branch block. 
 66
 
Table 9: 
DDYS 
No (n = 33) Yes (n = 7) Control (n = 20) 
 Mean S D Mean S D Mean S D F Sig. 
Tricuspid late velocity 35.39 4.41 44.29 4.92 38.65 4.74 11.82 0.000 
Tricuspid DT 171.48 11.09 196.43 11.63 177.15 5.75 19.17 0.000 
Tricuspid early by late 1.22 0.24 0.91 0.22 1.20 0.16 6.13 0.004 
Mitral late velocity 49.33 5.39 64.86 17.81 45.15 4.20 18.24 0.000 
Mitral Early by late 1.45 0.17 1.23 0.32 1.21 0.16 11.79 0.000 
Mitral DT 171.67 13.20 178.71 17.28 158.10 5.82 11.41 0.000 
Pul. Artery Sys. Pressure 20.82 12.53 40.00 19.32 18.20 3.55 9.88 0.000 
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DISCUSSION 
As per study by Fredrick M Wigley & Laura K Hummers et al(1) the 
prevalence of SSc is higher in females than in males(3:1), & the difference is 
greater in younger age group(7:1) .(9)  
In my study also there is a female preponderance with a female :male 
ratio of 12:1.The average age of onset is 50 years.(1). This is in contrast to 
my cohort of patients where age of onset is much younger(mean age is 35.8 
years+SD 10)  
The results indicate that unrecognized elevation of PASP is present in 
significant (22.5%) of patients in my study. Only 3 patients in total cohort 
had evidence of Pulm. HT by physical examination & ECG or both .the 
prevalence of pulmonary symptoms were similar in patients with or without 
Pulm.HT. Thus clinical assessment did not have Discriminant power with 
regard to presence or absence of Pulm.HT. 
In a study by R.W.Battle,M.A Davitt(3) et al the prevalence of 
patients with limited type was 85% & that of diffuse was 15% . in my study 
the ratio of limited to diffuse was 75:25%( 30:10). 
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In the same study the prevalence rate of Pulm.HT in their cohort of 34 
patients was 12 (35%). In my study the prevalence was lower (22.5%).  
The gold standard for assessing pulmonary artery pressure is right 
heart catheterization. However as catheterization is invasive & As Doppler 
echocardiography and cardiac catheterization have been reported to have a 
correlation of between 0.89 and 0.97 in cardiac causes of pulmonary 
hypertension (83), we have not undertaken catheterization of our SSc 
patients. 
Six other patients who had undergone PFT & HRCT for symptoms of 
dyspnea Had ILD but no Pulm.HT.  
In a study by Ungerer RG, Tashkin et al(6), indicate that specific 
noninvasive studies are helpful in assessing the likelihood of normal or 
definitely elevated pulmonary artery pressures in patients with progressive 
systemic sclerosis, but patients with mild pulmonary hypertension are not 
likely to be identified by these noninvasive studies. 
SSc pulmHt patients are unusual in that they become symptomatic & 
develop reduced cardiac output at relatively low pulmonary pressures. 
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Echo assessment of TG is traditionally regarded as accurate technique. 
However under or overestimation are well known to occur. Overestimates 
are rare. underestimation is are due to either absence of TR Jet or inability to 
obtain full alignment with regurgitation jet.(83)  
Rich etal(45) & Richards et al(68) have demonstrated variations upto 
30 % within 24 hours in pulmonary artery pressure.  
One patient had reversible elevation of pulmonary artery pressure.Its 
probably due to raynauds phenomenon occurring in pulmonary vasculature.  
Pulmonary parenchymal abnormalities are recognized with increased 
with increased frequency as a complication of SSc patients. In patients with 
CREST syndrome as many as 60-70% develop abnormal results in PFT’s 
despite significantly lower incidence of either symptoms of dyspnea or 
radiographic abnormalities. 
In this setting four major pattern of Pulmonary injury have been 
described, including vascular changes with or without PulmHT, an usual 
interstitial pneumonitis pattern(UIP) , small airways disease or a 
combination of these. Lung biopsy was not done since it may have harmful 
complications 
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Of these isolated Pulmonary vascular injury is most common 
histologic feature occurring in upto 50 % of autopsy in CREST syndrome. 
Typically patients present with exertional dyspnea . Early identification of 
PulmHT at a potentially reversible stage can modify the natural course of 
disease. 
Because primary diastolic dysfunction is an important cause of heart 
failure, as it often is a silent alteration preceding systolic dysfunction (39), 
knowledge of this complication in patients with SSc without clinically 
evident cardiac disease may be important to improve patient survival. The 
early detection of cardiopulmonary involvement in SSc is clearly desirable 
both for optimal treatment and for implementation of preventive measures in 
the early stages of the disease. 
The extent of RV diastolic dysfunction was not related to the duration 
of the disease or to the SSc skin score. in the present group of patients with 
SSc, LV function was normal, RV systolic function was preserved, but BV 
diastolic function was disturbed. This was evidenced by abnormal relaxation 
and filling properties, together with RV hypertrophy 
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These abnormalities were defined using both conventional Doppler 
echocardiography and Doppler tissue imaging (DTI). The hallmarks of SSc 
heart disease are myocardial fibrosis and ischemia. Studies (55) have 
demonstrated that intermittent coronary vasospasm, similar to Raynaud 
phenomenon, is prevalent in patients with SSc. The pattern of RV &LV 
diastolic disturbance seen in the present study could therefore be related to 
myocardial fibrosis and/or ischemia, both of which are known to affect 
ventricular relaxation and filling and are characterized by reduced E-wave 
velocity. 
 Detection of abnormalities in RV diastolic function might provide a 
means of identifying patients at risk for progressive heart failure. 
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CONCLUSIONS 
Scleroderma is higher in females than in males. 
Pulmonary hypertension occurs in a significant proportion of patients 
with scleroderma. More often its is asymptomatic. 
Symptoms consistent with PAH have no Discriminant power to 
differentiate those with or without elevated PASP. 
Its more commonly associated with ILD in diffuse disease, but can 
occur without lung or heart abnormalities in limited form (isolated PulmHT).  
The ratio of patients with limited to diffuse is 3:1. 
Mild or early intermittent pulmonary hypertension are not likely to be 
identified by these non-invasive studies &  hence mild PulmHT cannot be 
excluded in other patients. 
There is no statistically significant difference between patients with or 
without PulmHT when compared by type of SSc ,age ,sex ,duration of 
disease or CRP   
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When comparing Echo and Doppler differences between Patients 
With SSc and controls there was a significant difference between the two 
groups regarding the right ventricular cardiac chamber dimensions. 
 There was a significant difference in the estimated pulmonary artery 
systolic pressure between patients with and without ventricular diastolic 
dysfunction.  
Raynaud phenomenon within the lung is a possibility. 
 Diastolic dysfunction of RV, LV or both can occur in SSc, which can 
occur with or without the presence of PulmHT or systemic hypertension. 
More often it is asymptomatic. 
 The extent of RV diastolic dysfunction was not related to the duration 
of the disease or to the SSc skin score. 
The hallmarks of SSc heart disease are myocardial fibrosis and 
ischemia. Intermittent coronary vasospasm, similar to Raynaud 
phenomenon, is prevalent in patients with SSc. The pattern of RV &LV 
diastolic disturbance seen in the present study could therefore be related to 
myocardial fibrosis and/or ischemia.  
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Doppler echocardiography is a sensitive and non-invasive method of 
detecting cardiac abnormalities and systolic and/or diastolic function and for 
detecting pulmonary hypertension. 
Since so many therapeutic options are in the offing for management of 
PulmHT early detection is useful in altering the natural course of disease & 
in decreasing morbidity & mortality & to monitor the progression of disease. 
Detection of abnormalities in diastolic function might provide a 
means of identifying patients at risk for progressive heart failure. 
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LIMITATION OF THE STUDY 
• In my study, I did not do diffusing capacity of carbon monoxide 
(DLCO) because of its limited availability and cost. 
• For patients with isolated pulmonary hypertension, I did not 
rule out states of hypercoagulability like antiphospholipid 
antibody syndrome (or) thromboembolic phenomena by 
investigations like pulmonary angiography and ventilation / 
perfusion scans. 
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PROFORMA 
STUDY ON PULMONARY HYPERTENSION &DIASTOLIC 
DYSFUNCTION IN SCLERODERMA 
NAME: 
AGE: 
SEX: 
DISEASE DURATION: 
HISTORY OF PRESENTING COMPLAINTS: 
1. COUGH   YES/NO 
2.  EXPECTORATION  YES/NO 
3.  DYSPNEA  YES/NO 
4.  ORTHOPNEA  YES/NO 
5.  PND  YES/NO 
6.  CHEST PAIN  YES/NO 
7.  PALPITATIONS  YES/NO 
8.  SYNCOPE  YES/NO 
9.  CYANOSIS  YES/NO 
10.  WEIGHT LOSS  YES/NO 
11. OTHER COMPLAINTS  YES/NO 
12. RAYNAUDS PHENOMENON   YES/NO 
TREATMENT HISTORY: 
HISTORY OF DRUG INTAKE: YES/NO HOW MANY YEARS 
GENERAL EXAMINATION 
• Conscious 
• Temperature 
• Pallor 
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• Icterus 
• Cyanosis 
• Clubbing  
•  Lymphadenopathy  
• Pedal edema 
Pulse Rate:                                                          Blood pressure:                            
EXAMINATION OF SYSTEMS 
Cardiovascular System: 
CHEST WALL DEFORMITIES:                     YES/NO 
MURMURS               YES/NO 
RVH       YES/NO 
RESPIRATORY SYSTEM: 
INSPIRATORY CREPTS  : YES/NO 
PLEURAL EFFUSION    :YES/NO 
CENTRAL NERVOUS SYSTEM: 
INVESTIGATIONS 
1.  COMPLETE BLOOD COUNT 
Hemoglobin 
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Total Count 
Differential Count 
ESR 
2.  C REACTIVE PROTEIN 
3.  BLOOD GLUCOSE 
4.  BLOOD UREA 
5.  SERUM CREATININE 
6.  SERUM ELECTROLYTES 
                                          Albumin 
                                           Globulin 
7.  ANA 
8. SKIN BIOPSY  
9.  X-RAY CHEST PA VIEW 
12. ELECTROCARDIOGRAPY 
13. HRCT 
14. ECHOCARDIOGRAPHY (Inclusive of Doppler) 
1. Left atrial enlargement 
2. Right atrial enlargement 
3. Pericardial effusion 
4. Left ventricle ejection fraction (EF %)OF LV 
5. Fractional shortening (FS %) OF RPH 
6. Tricuspid regurgitation / TRPG 
7. Transmitral flow velocity (Em/Am Velocity) 
8. Transtricuspid flow velocity (Et/At Velocity)  
9. Deceleration time 
10. Pulmonary artery pressure (PAP) 
11Doppler Tissue Imaging (Mitral annulus / Tricuspid annulus)
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CHARTS&PICTURES 
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DIASTOLIC DYSFUNCTION-2D ECHO 
 93
 
 
 94
0
0.5
1
1.5
2
2.5
3
N
O
.
 
O
F 
PA
TI
EN
TS
FEMALES MALES
SUBGROUPING OF PATIENTS WITH DIASTOLIC 
DYSFUNCTION
RV DIASTOLIC DYSFUNTION WITH PHT
RV DIASTOLIC DYSFUNTION WITH OUT PHT
LV DIASTOLIC DYSFUNTION WITH SHT
LV DIASTOLIC DYSFUNTION WITHOUT SHT
BOTH RV & LV DIASTOLIC DYSFUNTION WITH PHT
BOTH RV & LV DIASTOLIC DYSFUNTION WITHOUT PHT
 
 
 95
MASTER CHART 
age sex pasp RA LA RVTH FAS EF TRE/A DT MIITE/A DT EM/AM
Meenakshi 24 0 18 9.4 10.4 4 40 65 1.4 185 1.3 155
Mallika 34 0 16 8.4 9.6 3 44 66 1 176 1.2 160
Vasanthi 20 0 24 10.4 8.4 5 38 70 1.3 170 1.4 145
Dharmalingam 40 1 22 9.4 10.4 4 40 65 1.4 165 1.2 150
Parimala 35 0 12 12.2 12 4 44 60 1.3 170 1.4 155
Thangam 28 0 21 8.2 20 6 40 62 1 174 1 157
Krishnan 20 1 19 10.4 14.2 30 41 63 1.2 171 1.4 168
Mohamed Ali 42 0 13 12.8 10 18 40 64 1.1 180 1.1 156
Renuka 33 0 15 11.7 17.4 23 41 62 1.4 175 1.3 166
Chandrasekar 41 1 23 8.4 21.6 40 45 64 1 178 1 153
Rathnakiumari 30 0 14 14.6 18.2 28 44 66 1.3 181 1.2 159
Pitchayee 20 0 20 12.8 14.2 21 42 61 1.2 178 1.4 164
Lakshmi 22 0 16 13 9.2 12 40 66 1.3 180 1.3 159
Muthulakshmi 25 0 22 17 18.2 8 41 60 1 175 1 161
Radha 40 0 16 19.4 17.6 31 43 68 1.4 188 1 160
Janagam 32 0 18 10.2 12.2 33 42 63 1.2 182 1.4 163
Jeyalaksmi 38 0 21 21.4 13.8 22 40 67 1 172 1.1 152
Rajeswari 24 0 15 14.8 11.6 12 44 70 1.3 179 1 161
Jamela Begum 21 0 22 20 18.2 25 42 62 1.1 184 1.3 165
Tamilarasi 38 0 17 15.2 16.4 24 45 68 1 180 1.2 153
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MASTER CHART 
 RVD RVTH DUR LVEF DDYS PAH AGE LCC dif SEX ILD EM/AM ET/AT MITE MITA E/A DT TR E TR A E/A DT FAS 
vijayalak 2.4 4 4 66 0 0 22 1 0 0 0 1.12 1.28 70 45 1.6 166 52 34 1.52 176 44 
laksmi 2 4 2 74 0 25 45 1  0 0 1.4 1.25 68 52 1.3 170 40 33 1.21 188 42 
banumathi 1.8 3 3 65 1 0 48 1  0 0 1.2 0.8 72 50 1.4 172 39 48 0.92 206 42 
RAJESWARI 1.8 5 3 66 0 0 36 1  0 0 1.23 1.34 70 48 1.5 157 36 31 1.16 160 40 
v jaya 1.5 5 2 70 0 56 46  1 0 1 1.36 1.42 66 40 1.7 178 48 40 1.2 176 40 
kanaga 15 4 9 75 0 0 24 1  0 1 1.42 1.38 64 54 1.2 166 36 30 1.2 165 43 
chinnamal 14 4 2 72 0 0 27 1  0 0 1.33 1.24 71 48 1.5 214 47 40 1.17 160 40 
veronica 16 3 2 68 0 0 29  1 0 0 1.37 1.18 84 46 1.8 168 39 32 1.21 175 42 
kala 2 4 5 65 0 46 29 0 1 0 0 1.18 1.55 73 53 1.4 170 44 36 1.22 166 44 
rajammal 2.4 4 2 62 0 0  1    1.24 1.16 69 52 1.3 186 46 40 1.15 186 45 
rukmini 2 4 6 68 0 42 45 1  0 0 1.4 1.54 66 40 1.7 162 48 33 1.45 160 50 
naseera 2.2 5 5 70 0 42 37 1  0 0 1.32 1.61 80 49 1.6 170 39 31 1.25 166 44 
anitha 1.6 4 5 62 0 0 16 1  0 0 1.37 1.42 80 55 1.5 164 42 34 1.23 154 46 
susela 17 4 5 63 0 0 49 1  0 0 1.28 1.54 76 50 1.5 192 45 37 1.21 176 48 
maliga 2.2 6 2 75 0 0 35 1    1.26 1.37 70 48 1.5 182 46 40 1.15 170 45 
shanthi 1.4 5 7 63 0 0 38 1  0 0 1.2 1.28 68 44 1.5 176 50 40 1.22 160 41 
padmavathi 2.5 4 4 74 0 0 30 1  0 1 1.39 1.29 83 50 1.7 156 38 25 1.52 166 43 
manimegalai 1.4 4 3 75 0 0 41 1    1.34 1.33 66 42 1.6 174 48 33 1.45 166 46 
chinapa 18 4 5 66 0 0 41 1  1  1.26 1.65 82 52 1.6 157 46 32 1.43 149 48 
malliga 14 5 2 60 0 0 35 1  0 0 1.14 1.38 77 47 1.6 182 39 30 1.3 176 32 
gandimathi 19 8 2 68 0 0 33 1  0 0 1.3 1.28 80 60 1.3 166 47 40 1.17 172 50 
prabavati 19 5 3 65 0 0 33 0 1 0 1 1.4 1.36 60 49 1.2 142 44 36 1.2 157 48 
PARTHBAN 18 3 1 60 0 0 50  1 1 1 1 1.45 70 50 1.4 170 40 30 1.3 167 41 
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 RVD RVTH DUR LVEF DDYS PAH AGE LCC dif SEX ILD EM/AM ET/AT MITE MITA E/A DT TR E TR A E/A DT FAS 
citra 16 4 3 65 0 0 27  1 0 1            
sujatha 14 4 2 55 0 0 19  1 0 0 1.36 1.18 60 42 1.4 152 48 34 1.4 176 45 
boomadevi 18 6 2 65 0 34 38 1  0 0 1.27 1.34 67 49 1.4 170 40 32 1.25 180 40 
revathi 16 5 4 62 0 22 26 1  0 0 1.38 1.42 72 54 1.3 168 49 40 1.21 172 42 
jamina 15 5 1 62 0 0 24 1  0 0 1.54 1.29 79 50 1.6 178 42 36 1.16 186 45 
bhimrao 20 5 3 56 0 0 29 1  1 0 1.2 1.18 64 42 1.5 180 44 35 1.25 188 46 
rajammal 16 4 2 66 0 20 50 1 0 0 0 1.36 1.26 78 52 1.5 164 46 38 1.21 190 48 
saraswathy 18 4 5 64 0 0 62 1 0 0 1 1.32 1.24 60 43 1.4 182 38 31 1.22 174 42 
kamala 16 3 3 58 0 0 45 1 0 0 0 1.16 1.35 66 48 1.4 170 48 40 1.2 180 40 
sulochana 20 8 2 77 1 52 35 1  0 0 0.9 1.33. 80 60 1.3 173 38 47 0.8 206 44 
malati 16 4 3 74 1 24 19 1  0 0 0.8 1.23 76 52 1.5 163 40 48 0.83 198 45 
anthoniam 16 4 4 66 1 52 28 0 1 0 1 0.78 1.1 74 62 1.2 179 36 43 0.84 188 40 
devaki 16 4 2 60 1 20 35 1  0 0 1.25 0.8 80 50 1.6 160 40 46 0.76 201 46 
Jeeva 17 12 2 70 1 72 40 1  1 1 0.77 0.82 70 90 0.8 198 35 44 0.79 202 38 
paremes 16 5 3 64 1 36 48 0 1 0 1 1.2 0.84 75 90 0.8 206 48 34 1.4 174 40 
Sankari 20 4 2 65 0 0 30 0 1 0 0 1.3 1.2 66 60  190 49 39 1.25 182 38 
bimarao 16 4 3 65 0 0 29 1  0 0 1.3 1.4 76 60  176 55 44 0 186 40 
 
